Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study.
All-cause mortality
Apolipoprotein A1
Apolipoprotein B
Apolipoproteins
Breast cancer
Cancer
Circulating lipids
Cohort study
Distant recurrence
Dyslipidemia
Lipids
Loco-regional recurrence
Prognosis
Recurrence
Survival
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
18
08
2021
accepted:
17
11
2021
pubmed:
27
11
2021
medline:
15
2
2022
entrez:
26
11
2021
Statut:
ppublish
Résumé
Examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Circulating lipid levels were measured in blood sampled upon enrollment in the female MDCS cohort (N = 17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991 and 2014. Follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or 5 years of follow-up. We estimated the incidence rates of recurrence at 5 years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). We enrolled 850 eligible patients. During the 5 years of follow-up, 90 invasive breast cancer recurrences were diagnosed over 3807 person-years. In multivariable analyses, high baseline levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR = 2.30 [95% CI 1.13-4.68]). However, high baseline levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR = 1.23 [95% CI 0.68-2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR = 1.34 [95% CI 0.70-2.58]) or all-cause mortality (tertile 3 vs. 1, HR = 1.12 [95% CI 0.61-2.05]). High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcomes.
Identifiants
pubmed: 34825306
doi: 10.1007/s10549-021-06462-7
pii: 10.1007/s10549-021-06462-7
pmc: PMC8831289
doi:
Substances chimiques
Apolipoprotein A-I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
611-621Informations de copyright
© 2021. The Author(s).
Références
BMC Cancer. 2014 Feb 26;14:132
pubmed: 24571647
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Trends Endocrinol Metab. 2014 Dec;25(12):649-55
pubmed: 25458418
J Intern Med. 1993 Jan;233(1):45-51
pubmed: 8429286
Exp Mol Med. 2018 Nov 14;50(11):1-12
pubmed: 30429453
Eur J Cancer Prev. 2001 Dec;10(6):489-99
pubmed: 11916347
Breast Cancer Res Treat. 2010 Jun;121(3):651-60
pubmed: 19882245
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Breast. 2017 Apr;32:1-6
pubmed: 27939967
Cancer Med. 2019 Nov;8(16):7032-7043
pubmed: 31573738
Eur J Epidemiol. 2014 Feb;29(2):119-32
pubmed: 24519551
J Clin Med. 2020 Sep 02;9(9):
pubmed: 32887448
Clin Chem Lab Med. 2007;45(9):1219-23
pubmed: 17663634
Oncoscience. 2016 Jul 22;3(7-8):242-257
pubmed: 27713913
Electrophoresis. 2006 Apr;27(8):1641-50
pubmed: 16550499
Breast Cancer Res Treat. 2020 Jul;182(2):401-409
pubmed: 32500397
Eur J Cancer. 2001 Aug;37(12):1510-3
pubmed: 11506958
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Cancer Cell. 2015 Jan 12;27(1):57-71
pubmed: 25584894
Clin Chem. 2009 Mar;55(3):407-19
pubmed: 19168552
Endocr Relat Cancer. 2017 Jul;24(7):339-349
pubmed: 28442559
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Sci Rep. 2016 Nov 03;6:36387
pubmed: 27808249
BMC Cancer. 2018 Jun 15;18(1):654
pubmed: 29902993
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Am J Clin Nutr. 2016 Jun;103(6):1397-407
pubmed: 27099252
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1074-81
pubmed: 18483328
JAMA Cardiol. 2019 Dec 1;4(12):1287-1295
pubmed: 31642874
Cancer. 2020 Apr 1;126(7):1559-1567
pubmed: 31840240
Cancers (Basel). 2019 Aug 01;11(8):
pubmed: 31374929
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Diabetes. 2009 Aug;58(8):1887-92
pubmed: 19491209
Int J Cancer. 2016 Jun 1;138(11):2648-56
pubmed: 26804063
Biochim Biophys Acta. 2016 Jul;1861(7):566-83
pubmed: 26968096
Br J Cancer. 1957 Sep;11(3):359-77
pubmed: 13499785
Endocrinol Metab (Seoul). 2015 Jun;30(2):208-15
pubmed: 26194080
Breast Cancer Res Treat. 1996;40(3):265-70
pubmed: 8883969
Sci Rep. 2018 Jul 10;8(1):10383
pubmed: 29991730
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Intern Med. 1993 Jan;233(1):63-7
pubmed: 8429289
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
J Clin Oncol. 1996 Oct;14(10):2738-46
pubmed: 8874335
Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):727-33
pubmed: 8672989
BMC Cancer. 2018 Feb 9;18(1):171
pubmed: 29426294